The elimination is faster in children than in adults. The elimination half-life in young children (0.5 –2 years) is 3.1 ± 1.8 hours; Tmax is 2.0 ± 1.3 hours, the volume of distribution is 0.44 ± 0.19 l/kg and Cmax is 390 ± 135 ng/ml. The oral clearance in this age group is 2.13 ± 1.15 ml/min/kg. In children aged 2–6 years, the elimination half-life is 5.55 ± 0.98 hours; the clearance is 1.27 ± 0.80 ml/min/kg. The elimination half-life increases in children older than 6 years to approximately 6–7 hours
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis), chronic idiopathic urticaria and acute food allergies. |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
When the creatinine clearance is > 50 ml/min/1.73m²:
Dose adjustment is not required
When the creatinine clearance is 10-50 ml/min/1.73m²:
< 12 years: 100% of the normal dose each time, dosage interval 24 hours
≥ 12 years: 50% of the normal dose each time, dosage interval 24 hours
When the creatinine clearance is < 10 ml/min/1.73m²:
general recommendations cannot be given
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Headaches, dizziness, dry mouth, pain in the lower abdomen, nausea, pharyngitis, rhinitis, nosebleed, sleepiness, oculogyric crisis (above all in children), agitation, dyskinesia, enuresis and sedation. In young children: diarrhoea, sleepiness, fatigue and rhinitis.
A case has been described in the literature of acute generalized exanthematous pustulosis (AGEP).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
The plasma clearance is reduced in patients with renal or hepatic insufficiency. Use in children aged < 2 years is not recommended because of certain excipients in the liquid formulation.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Piperazine derivatives | ||
|---|---|---|
| R06AE03 | ||
| Other antihistamines for systemic use | ||
|---|---|---|
| R06AX26 | ||
| R06AX13 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.